← Patent-cliff monitor small molecule REZDIFFRA RESMETIROM
Loss of exclusivity February 2045 latest FDA-listed patent expiry
Drug detail Brand name REZDIFFRA Active ingredient RESMETIROM Strength 80MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval March 2024 Marketing status RX
Listed patents Patent Expires Type 12377104 February 2045 use U-3861 12667575 February 2045 use U-4567 12661359 January 2042 use U-4568 9266861 September 2033 substance, product 11564926 September 2033 substance, product 10376517 September 2033 use U-3861 11986481 September 2033 use U-3861 7452882 September 2027 substance, product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.